COVID-19疫情期间伦巴第无症状癌症患者[18F]-FDG-PET/CT检出间质性肺炎发生率增加:偶然还是感染?
该回顾性研究比较了COVID-19疫情高峰期与对照期癌症患者[18F]-FDG PET/CT上间质性肺炎的发生率,并对比区域COVID-19流行病学数据。结果显示疫情期间间质性肺炎发生率显著高于对照期(4.2% vs 1.9%,p=0.013),且影像异常曲线与区域COVID-19发病率重叠(Spearman相关系数=1)。作者认为[18F]-FDG PET/CT可作为识别可疑COVID-19病例的哨兵手段。
要点
- 疫情期间癌症患者PET/CT中间质性肺炎发生率显著高于对照期(4.2% vs 1.9%)。
- 影像异常发生曲线与伦巴第地区COVID-19发病率高度重叠。
- 核医学医师应对间质性肺炎征象保持主动监测,尤其在新感染高峰预期时。
核心结论
- COVID-19疫情期间[18F]-FDG PET/CT上间质性肺改变显著增加。
- 影像异常发生率曲线与一般人群流行病学数据相似。
- 支持将[18F]-FDG PET/CT作为识别可疑COVID-19病例的哨兵手段。
研究设计与样本
- 回顾性分析贝加莫Humanitas Gavazzeni核医学科癌症患者的[18F]-FDG PET/CT扫描。
- 比较2019年12月至2020年5月(COVID-19疫情期)与2018年12月至2019年5月(对照期)两个6个月时段。
- 共纳入1298例患者,疫情期575例,对照期723例。
- 采用分层Cochran-Mantel-Haenszel检验比较两组,卡方检验或Fisher精确检验及t检验或Wilcoxon检验比较变量分布。
主要发现
- 疫情期与对照期患者在年龄、疾病或扫描指征上无统计学差异(p>0.05)。
- 疫情期24例(4.2%)和对照期14例(1.9%)观察到间质性肺炎征象,差异有统计学意义(p=0.013)。
- 仅考虑1月至5月时差异更显著,3月达到峰值(7/83例,8.4% vs 3/134例,2.2%,p=0.001)。
- 间质性肺炎诊断曲线与伦巴第地区COVID-19发病率重叠(Spearman相关系数=1)。
- 两队列影像学数据无差异。
临床怎么用
- 核医学医师应继续主动监测[18F]-FDG PET/CT上的间质性肺炎表现。
- 在新感染高峰预期时,对可疑COVID-19病例可转诊进行额外确诊检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The study aimed to compare the incidence of interstitial pneumonia on [18F]-FDG PET/CT scans between two 6-month periods: (a) the COVID-19 pandemic peak and (b) control period. Secondly, we compared the incidence of interstitial pneumonia on [18F]-FDG PET/CT and epidemiological data from the regional registry of COVID-19 cases. Additionally, imaging findings and the intensity of [18F]-FDG PET/CT uptake in terms of maximum standardized uptake value (SUVmax) were compared. METHODS: We retrospectively analyzed [18F]-FDG PET/CT scans performed in cancer patients referred to nuclear medicine of Humanitas Gavazzeni in Bergamo from December 2019 to May 2020 and from December 2018 to May 2019. The per month incidence of interstitial pneumonia at imaging and the epidemiological data were assessed. To evaluate the differences between the two symmetric groups (period of COVID-19 pandemic and control), the stratified Cochran-Mantel-Haenszel test was used. Chi-square test or Fisher's exact test and t test or Wilcoxon test were performed to compare the distributions of categorical and continuous variables, respectively. RESULTS: Overall, 1298 patients were included in the study. The two cohorts-COVID-19 pandemic (n = 575) and control (n = 723)-did not statistically differ in terms of age, disease, or scan indication (p > 0.05). Signs of interstitial pneumonia were observed in 24 (4.2%) and 14 patients (1.9%) in the COVID-19 period and the control period, respectively, with a statistically significant difference (p = 0.013). The level of statistical significance improved further when the period from January to May was considered, with a peak in March (7/83 patients, 8.4% vs 3/134 patients, 2.2%, p = 0.001). The curve of interstitial pneumonia diagnosis overlapped with the COVID-19 incidence in the area of Lombardy (Spearman correlation index was equal to 1). Imaging data did not differ among the two cohorts. CONCLUSIONS: Significant increase of interstitial lung alterations at [18F]-FDG PET/CT has been demonstrated during the COVID-19 pandemic. Additionally, the incidence curve of imaging abnormalities resulted in resembling the epidemiological data of the general population. These data support the rationale to adopt [18F]-FDG PET/CT as sentinel modality to identify suspicious COVID-19 cases to be referred for additional confirmatory testing. Nuclear medicine physicians and staff should continue active surveillance of interstitial pneumonia findings, especially when new infection peak is expected.
引用
- Setti L, Bonacina M, Meroni R, et al. Increased incidence of interstitial pneumonia detected on [18F]-FDG-PET/CT in asymptomatic cancer patients during COVID-19 pandemic in Lombardy: a casualty or COVID-19 infection? Eur J Nucl Med Mol Imaging. 2020. PMID: 32909090. doi:10.1007/s00259-020-05027-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。